Latest Bone Regeneration News

Page 3 of 3

Orthocell Surges with Record Revenue and US Market Breakthrough for Remplir™

Orthocell Limited has reported a record FY2025 revenue of A$9.19 million, driven by strong sales of its nerve repair product Remplir™ in Australia and a promising US market launch following FDA clearance.

Ada Torres

9 July 2025

Browse the archive

Full archive

Nov 2026 Oct 2026 Sept 2026 Aug 2026 July 2026 June 2026 May 2026 Apr 2026